v3.24.1.1.u2
Collaboration and License Agreements and Supply Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
shares
Nov. 30, 2023
USD ($)
Installment
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
Program
PerformanceObligation
Apr. 30, 2022
USD ($)
Jul. 31, 2018
Program
Mar. 31, 2024
USD ($)
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Accounts receivable, reserve for credit losses   $ 0           $ 0   $ 0    
Common stock, shares issued | shares   62,456,546           62,456,546   61,009,829    
Common stock value issued   $ 62,000           $ 62,000   $ 61,000    
Vaxcyte, Inc.                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
First installment milestone payment received     $ 50,000,000                  
Number of installments | Installment     2                  
Additional milestone payment receivable     $ 25,000                  
Additional milestone payment                   60,000,000    
Blackstone Life Sciences                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment received       $ 140,000,000                
2015 License Agreement | Blackstone Life Sciences | Royalty                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment received       $ 140,000,000                
Revenue interest percentage       4.00%       4.00%        
2018 Merck Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Deferred revenue   0           $ 0   0    
2018 Merck Agreement | Merck Sharp & Dohme Corp                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Number of target programs | Program             2          
Revenue recognition aggregate contingent payments eligible to receive                     $ 500,000,000  
Milestone method revenue recognition description               If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low-teen digit percentages on the worldwide sales of any commercial products that may result from the collaboration.        
2020 Merck Master Services Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Deferred revenue   0           $ 0   0    
Supply Agreement | Vaxcyte, Inc.                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Reimbursements expenses accruals   7,400,000           7,400,000   6,900,000    
Reimbursements expenses               1,600,000 $ 1,900,000      
Astellas License and Collaboration Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Deferred revenue   61,800,000           61,800,000   69,000,000    
Number of target programs | Program         3              
Upfront payment received               90,000,000        
Transaction price         $ 90,000,000              
Estimated service period         4 years              
Recognition of up front payment         $ 89,100,000              
Upfront payment revenue not recognized               32,600,000        
Nonrefundable, non-creditable upfront payment receivable                       $ 90,000,000
Number of performance obligations | PerformanceObligation         4              
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate   422,500,000           422,500,000        
Astellas License and Collaboration Agreement | Future Services on Collaboration Joint Steering Committee ("JSC")                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Recognition of up front payment         $ 900,000              
Tasly License Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Maximum potential payments related to development regulatory commercialization contingent payments and milestones           $ 350,000,000            
Reduction of research and development expenses recognized               0 $ 0      
Initial licensing payment due           25,000,000            
Initial licensing payment in escrow           $ 15,000,000            
Revenue recognized from contingent payment                   5,000,000    
Income tax charge related to contingent payment                   $ 500,000    
Maximum refund period on termination of study                   30 days    
Contingent payment recognized as deferred revenue                   $ 5,000,000    
Withholding tax on deferred revenue                   $ 500,000    
Ipsen Agreement                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Milestone payment received   $ 7,000,000                    
Upfront license fee               $ 50,000,000        
Common stock, shares issued | shares   4,827,373           4,827,373        
Common stock value issued   $ 25,000,000           $ 25,000,000        
Additional purchase of Common Stock   $ 10,000,000           $ 10,000,000        
Percentage of VWAP premium   0.17                    
Payment related to development and regulatory milestone   $ 447,000,000                    
Payments related to sales milestone   $ 360,000,000                    
Ipsen Agreement | Subsequent Event                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront license fee $ 50,000,000